Last $95.32 USD
Change Today -0.90 / -0.94%
Volume 395.3K
BLUE On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

bluebird bio inc (BLUE) Snapshot

Open
$95.66
Previous Close
$96.22
Day High
$97.00
Day Low
$94.43
52 Week High
01/14/15 - $106.23
52 Week Low
05/9/14 - $17.40
Market Cap
3.1B
Average Volume 10 Days
445.9K
EPS TTM
$-1.74
Shares Outstanding
32.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BLUEBIRD BIO INC (BLUE)

bluebird bio inc (BLUE) Related Businessweek News

No Related Businessweek News Found

bluebird bio inc (BLUE) Details

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, as well as a phase I study in the United States for the treatment of severe SCD. The company also develops various CAR T cell products for liquid and solid tumor cancers. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

143 Employees
Last Reported Date: 02/25/15
Founded in 1992

bluebird bio inc (BLUE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $392.5K
Chief Operating Officer
Total Annual Compensation: $321.7K
Chief Scientific Officer
Total Annual Compensation: $307.2K
Compensation as of Fiscal Year 2013.

bluebird bio inc (BLUE) Key Developments

bluebird bio, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

bluebird bio, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of USD 6,386,000 against USD 6,335,000 a year ago. Loss from operations was USD 19,616,000 against USD 8,115,000 a year ago. Loss before income taxes was USD 19,544,000 against USD 8,081,000 a year ago. Net loss was USD 19,544,000 against USD 8,081,000 a year ago. Basic and diluted net loss per share was USD 0.67 against USD 0.34 a year ago. For the nine months, the company reported total revenue of USD 25,421,000 against USD 20,181,000 a year ago. Loss from operations was USD 60,626,000 against USD 24,947,000 a year ago. Loss before income taxes was USD 60,506,000 against USD 25,321,000 a year ago. Net loss was USD 48,709,000 against USD 25,321,000 a year ago. Basic and diluted net loss per share was USD 1.83 against USD 2.02 a year ago.

bluebird bio, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

bluebird bio, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

FDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major

bluebird bio, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to LentiGlobin BB305 Drug Product for the treatment of transfusion-dependent patients with beta-thalassemia major. LentiGlobin BB305 Drug Product aims to treat beta-thalassemia major and severe sickle cell disease by inserting a functional human beta-globin gene into the patient's own hematopoietic stem cells ex vivo and then returning those modified cells to the patient through an autologous stem cell transplantation. The FDA's Breakthrough Therapy designation is intended to expedite the development and review of a drug candidate that is planned for use to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus an organizational commitment involving FDA's senior managers with more intensive guidance from the FDA. Breakthrough Therapy designation does not however change the standards for approval.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLUE:US $95.32 USD -0.90

BLUE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fibrocell Science Inc $4.87 USD -0.28
Sangamo BioSciences Inc $16.82 USD -0.15
View Industry Companies
 

Industry Analysis

BLUE

Industry Average

Valuation BLUE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 111.2x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 104.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLUEBIRD BIO INC, please visit www.bluebirdbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.